367 related articles for article (PubMed ID: 18380812)
1. Economic evaluation of prostate cancer screening with prostate-specific antigen.
Imamura T; Yasunaga H
Int J Urol; 2008 Apr; 15(4):285-8. PubMed ID: 18380812
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.
Kobayashi T; Goto R; Ito K; Mitsumori K
Eur J Surg Oncol; 2007 Aug; 33(6):783-9. PubMed ID: 17408910
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
[TBL] [Abstract][Full Text] [Related]
4. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
Krahn MD; Coombs A; Levy IG
CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
Shteynshlyuger A; Andriole GL
J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
[TBL] [Abstract][Full Text] [Related]
6. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
Crawford ED; Abrahamsson PA
Eur Urol; 2008 Aug; 54(2):262-73. PubMed ID: 18556114
[TBL] [Abstract][Full Text] [Related]
7. Current status of PSA screening. Early detection of prostate cancer.
Pickles T
Can Fam Physician; 2004 Jan; 50():57-63. PubMed ID: 14761105
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of prostate-specific antigen as a screening test for prostate cancer.
Dorr VJ; Williamson SK; Stephens RL
Arch Intern Med; 1993 Nov; 153(22):2529-37. PubMed ID: 7694555
[TBL] [Abstract][Full Text] [Related]
9. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
Pienta KJ
Urology; 2009 May; 73(5 Suppl):S11-20. PubMed ID: 19375622
[TBL] [Abstract][Full Text] [Related]
10. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
Lim LS; Sherin K;
Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
[TBL] [Abstract][Full Text] [Related]
11. [Dissemination of evidence-based information about PSA test and prostatic cancer to physicians].
Norderhaug IN; Wisløff T; Fosså S; Sandberg S; Malde K; Forland F; Førde OH
Tidsskr Nor Laegeforen; 2004 Nov; 124(22):2893-5. PubMed ID: 15550959
[TBL] [Abstract][Full Text] [Related]
12. The case for prostate cancer screening.
Andriole GL
Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
Ito K
Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening in Greece: current facts.
Stamatiou K; Lardas M; Kostakos E; Koutsonasios V; Lepidas D
Urol J; 2009; 6(3):157-61. PubMed ID: 19711267
[TBL] [Abstract][Full Text] [Related]
15. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
16. Mass screening for prostate cancer. The Swedish Council on Technology Assessment in Health Care.
Int J Cancer Suppl; 1996; 9():1-72. PubMed ID: 8982323
[No Abstract] [Full Text] [Related]
17. Screening for prostate cancer.
Postma R; Schröder FH
Eur J Cancer; 2005 Apr; 41(6):825-33. PubMed ID: 15808952
[TBL] [Abstract][Full Text] [Related]
18. Serum prostate-specific antigen screening for prostate cancer: application of current evidence to model criteria.
Patel SH
Appl Health Econ Health Policy; 2003; 2(2):79-83. PubMed ID: 14619278
[TBL] [Abstract][Full Text] [Related]
19. The implementation of screening for prostate cancer.
van Leeuwen PJ; van Vugt HA; Bangma CH
Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):218-27. PubMed ID: 20680029
[TBL] [Abstract][Full Text] [Related]
20. [Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening].
Kobayashi T; Goto R; Hinotsu S; Ogawa O
Hinyokika Kiyo; 2013 Mar; 59(3):159-66. PubMed ID: 23633630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
